Elanco Animal Health (NYSE:ELAN) Issues Q3 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its third quarter 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.190-0.220 for the period, compared to the consensus estimate of 0.190. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.100-1.160 EPS.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Morgan Stanley raised their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday. Citigroup boosted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.73.

Elanco Animal Health Stock Down 0.6%

ELAN stock opened at $25.56 on Wednesday. The company’s 50 day moving average is $24.68 and its two-hundred day moving average is $24.09. Elanco Animal Health has a twelve month low of $13.76 and a twelve month high of $27.72. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The stock has a market cap of $12.77 billion, a P/E ratio of -51.12, a PEG ratio of 1.68 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts expect that Elanco Animal Health will post 1.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction on Friday, May 15th. The stock was bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 1.14% of the company’s stock.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds have recently added to or reduced their stakes in ELAN. Parallel Advisors LLC increased its position in Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after purchasing an additional 392 shares during the period. Lazard Asset Management LLC grew its holdings in Elanco Animal Health by 0.6% during the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares during the period. Meeder Advisory Services Inc. lifted its holdings in Elanco Animal Health by 4.8% in the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock valued at $254,000 after acquiring an additional 510 shares during the period. NewEdge Advisors LLC lifted its holdings in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the period. Finally, Arkadios Wealth Advisors boosted its position in shares of Elanco Animal Health by 1.2% during the 4th quarter. Arkadios Wealth Advisors now owns 52,868 shares of the company’s stock worth $1,196,000 after purchasing an additional 652 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.